Antagonist of C5aR prevents cardiac remodeling in angiotensin II-induced hypertension

American Journal of Hypertension

Volumn 27, Issue 6, 2014, Pages 857-864

  Zhang, Congcong ^a   Li, Yulin ^a   Wang, Chunxiao ^a   Wu, Yina ^a   Du, Jie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

blood pressure; cardiovascular damage; complement; hypertension; inflammation

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; MESSENGER RNA; PMX 53; PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACPHE(ORNITHINE-PRO-CYCLOHEXYLAMINE-TRP-ARG); CARDIOVASCULAR AGENT; COLLAGEN; COMPLEMENT COMPONENT C5A RECEPTOR; CTGF PROTEIN, MOUSE; CYCLOPEPTIDE; TGFB1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; CARDITIS; CONTROLLED STUDY; DRUG EFFICACY; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; HEART MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CARDIOVASCULAR AGENTS; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; HYPERTENSION; MICE, INBRED C57BL; MYOCARDIUM; PEPTIDES, CYCLIC; RECEPTOR, ANAPHYLATOXIN C5A; RNA, MESSENGER; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 84900873319     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt274     Document Type: Article

References (45)

1. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease, J Clin Invest 2007; 117:568-575.
2. Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci (Landmark Ed) 2012; 17:221-231.
3. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-1066.
4. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-1144.
5. Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, Taylor SM. Complement C5a inhibition reduces atherosclerosis in ApoE-/-mice. FASEB J 2011; 25:2447-2455.
6. Peng Q Li K, Smyth LA, Xing G, Wang N, Meader L, Lu B, Sacks SH, Zhou W. C3a and C5a promote renal ischemia-reperfusion injury. I Am Soc Nephrol 2012; 23:1474-1485.
7. Zhang H, Qin G, Liang G, Li J, Barrington RA, Liu DX. C5aR-mediated myocardial ischemia/reperfusion injury. Biochem Biophys Res Commun 2007; 357:446-452.
8. de Vries MR, Wezel A, Schepers A, van Santbrink PJ, Woodruff TM, Niessen HW, Hamming JF, Kuiper J, Bot I, Quax PH. Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res 2013; 97:311-320.
9. Wu MC, Brennan FH, Lynch JP, Mantovani S, Phipps S, Wetsel RA, Ruitenberg MJ, Taylor SM, Woodruff TM. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc Natl Acad Sei US A 2013; 110:9439-9444.
10. Gueler F, Rong S, Gwinner W, Mengel M, Brocker V, Schon S, Greten TF, Hawlisch H, Polakowski T, Schnatbaum K, Menne J, Haller H, Shushakova N. Complement 5a receptor inhibition improves renal allograft survival, J Am Soc Nephrol 2008; 19:2302-2312.
11. Li G, Fan RM, Chen JL, Wang CM, Zeng YC, Han C, Jiao S, Xia XP, Chen W, Yao ST. Neuroprotective effects of Argatroban and C5a receptor antagonist (PMX53) following intracerebral hemorrhage. Clin Exp Immunol 2013; e-pub ahead of print 11 October 2013.
12. Manthey HD, Woodruff TM, Taylor SM, Monk PN. Complement component 5a (C5a). Int J Biochem Cell Biol 2009; 41:2114-2117.
13. Woodruff TM, Pollitt S, Proctor LM, Stocks SZ, Manthey HD, Williams HM, Mahadevan IB, Shiels IA, Taylor SM. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease, J PharmacolExp Ther2005; 314:811-817.
14. Li Y Zhang C, Wu Y Han Y Cui W, Jia L, Cai L, Cheng J, Li H, Du J. Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensin II-induced cardiac fibrosis. Arterioscler Thromb Vase Biol 2012; 32:1662-1674.
15. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. CircRes 2009; 105:1164-1176.
16. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. CircRes 2010; 106:1675-1680.
17. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, Wagner O, Huber K, Minar E, Wojta J, Schillinger M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26:2294-2299.
18. Speidl WS, Katsaros KM, Kastl SP, Zorn G, Huber K, Maurer G, Wojta J, Christ G. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 2010; 208:285-289.
19. Pagano MB, Zhou HF, Ennis TL, Wu X, Lambris JD, Atkinson JP, Thompson RW, Hourcade DE, Pham CT. Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm. Circulation 2009; 119:1805-1813.
20. Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L, Zetoune FS, Su GL, Arbabi S, Sarma JV, Wang SC, Hemmila MR, Ward PA. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction, J Exp Med 2006; 203:53-61.
21. Engstrom G, Hedblad B, Berglund G, Janzon L, Lindgarde F. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. I Hum Hypertens 2007; 21:276-282.
22. Gan W, Wu J, Lu L, Xiao X, Huang H, Wang F, Zhu J, Sun L, Liu G, Pan Y Li H, Lin X, Chen Y Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population. PLoS One 2012; 7:e42010.
23. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN. Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97:716-724.
24. Jia LX, Qi GM, Liu O, Li TT, Yang M, Cui W Zhang WM, Qi YF, Du J. Inhibition of platelet activation by Clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. Cardiovasc Drugs Ther 2013; 27:521-530.
25. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction, J Exp Med 2007; 204:2449-2460.
26. Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology 2012; 217:1026-1033.
27. Ioannou A, Kannan L, Tsokos GC. Platelets, complement and tissue inflammation. Autoimmunity 2013; 46:1-5.
28. Shagdarsuren E, Bidzhekov K, Mause SF, Simsekyilmaz S, Polakowski T, Hawlisch H, Gessner JE, Zernecke A, Weber C. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2010; 122:1026-1036.
29. Banz Y, Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med 2012; 44:205-217.
30. de Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P Buurman WA. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils, J Immunol 2003; 170:3883-3889.
31. Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ, Du J. Reciprocal interaction between macrophages and T cells stimulates IFN-gamma and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS One 2012; 7:e35506.
32. Ma F, Li Y Jia L, Han Y Cheng J, Li H, Qi Y Du J. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2012; 7:e35144.
33. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(l). Mol Genet Metab 2000; 71:418-435.
34. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007; 74:207-212.
35. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-betal mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109:787-796.
36. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Muller D, Ganten D, Luft F, Mervaala E. Angiotensin II induces connective tissue growth factor gene expression via calcineu-rin-dependent pathways. Am J Pathol 2003; 163:355-366.
37. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis, J Mol Cell Cardiol 2000; 32:1805-1819.
38. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010; 10:220-230.
39. Hayata N, Fujio Y Yamamoto Y Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008; 370:274-278.
40. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload, J Clin Invest 2011; 121:2301-2312.
41. Rosenkranz S. TGF-betal and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63:423-432.
42. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, Arend WP, Holers VM. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice, J Immunol 2012; 188:1469-1478.
43. Lim H, Kim YU, Drouin SM, Mueller-Ortiz S, Yun K, Morschl E, Wetsel RA, Chung Y. Negative regulation of pulmonary Thl7 responses by C3a anaphylatoxin during allergic inflammation in mice. PLoS One 2012; 7:e52666.
44. Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, Glaab T, Erpenbeck Y Krug N, Braun A. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyper-responsiveness and airway inflammation. I Immunol 2005; 174:783-789.
45. Lajoie S, Lewkowich IP, Suzuki Y Clark JR, Sproles AA, Dienger K, Budelsky AL, Wills-Karp M. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol 2010; 11:928-935.